Search Results

Sequana Medical NV announces data from its North American pivotal POSEIDON study of the alfapump® demonstrating significantly improved quality of life focused on ascites symptoms and physical functions compared to baseline, which is not seen in refractory ascites patients enrolled contemporaneously in the prospective NACSELD3 cohort.

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces the agreed outcome of the “Day 100” meetingi with the US Food and Drug Administration, following receipt of the “Day 90” major deficiency Letter.

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces its financial results for the year ended 31 December 2023, and provides a business update and outlook for 2024 and beyond.

Sequana Medical NV announces that the American Medical Association has issued six new Category III Current Procedural Terminology codes for the alfapump system, an important step in facilitating reimbursement for the Company’s innovative medical device for the treatment of recurrent or refractory ascites due to liver cirrhosis.

Sequana Medical NV announces that all proposed resolutions submitted to the Extraordinary General Meeting of Shareholders were approved at the meeting held today at 09:00 am CET.

Sequana Medical NV announces that it has submitted a Premarket Approval application to the US Food and Drug Administration for alfapump, the Company’s fully implantable, wirelessly charged device for patients with recurrent or refractory ascites due to liver cirrhosis.

Conference call with live webcast by Sequana Medical today at 03:00 pm CEST / 09:00 am EST

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, will announce its half-year results ended 30 June 2023 on Thursday, 14 September 2023.